Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKRX Akorn (AKRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Akorn Stock (NASDAQ:AKRX) 30 days 90 days 365 days Advanced Chart Get Akorn alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.09▼$0.3252-Week Range N/AVolume1.19 million shsAverage Volume9.60 million shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAkorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Read More… Receive AKRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRX Stock News HeadlinesAkorn Reaches New 52-Week High (AKRX)May 15, 2023 | thestreet.comCarlin Consumer Health Names Scott Chapman Chief Executive Officer - Business WireOctober 20, 2022 | businesswire.comWarning: Elon’s $20k Robot Might Replace Your NannyTesla’s Robot Revolution Has Begun It’s official… Tesla’s robot revolution is underway… By the end of this year, Tesla plans to produce 600 new “Tesla Bots” per week… Tech insiders believe this could be the company’s next core driver of explosive growth. Some even believe it could be the catalyst that would push shares above the $1,000 mark. That’s essentially a 100% increase from today’s price…February 21, 2025 | WealthPress (Ad)Veterinary Eye Care Market Size to record USD 788.78 Million Growth at a CAGR of 4.65% by 2026, Evolving Opportunities with Bausch Health Co Inc. And Akorn Operating Co. - Technavio - PR NewswireOctober 10, 2022 | prnewswire.comA small fund wagered that Elon Musk would be forced to buy Twitter—and made a killing by betting against the crowd - FortuneOctober 9, 2022 | fortune.comDiuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth - Technavio - Yahoo FinanceSeptember 29, 2022 | finance.yahoo.comMoody's downgrades Akorn to Caa2; revises outlook to stable from positive - Moody'sSeptember 15, 2022 | moodys.comPrestige Consumer (PBH) Brands & E-commerce Strength Bode Well - NasdaqSeptember 2, 2022 | nasdaq.comSee More Headlines AKRX Stock Analysis - Frequently Asked Questions How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) posted its quarterly earnings data on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.45. The firm earned $204.69 million during the quarter, compared to analysts' expectations of $168.90 million. Akorn had a negative net margin of 55.64% and a positive trailing twelve-month return on equity of 8.53%. What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akorn investors own include Bristol-Myers Squibb (BMY), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC) and Quantenna Communications (QTNA). Company Calendar Last Earnings5/11/2020Today2/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AKRX CUSIP00972810 CIK3116 Webwww.akorn.com Phone847-279-6100FaxN/AEmployees2,227Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,770,000.00 Net Margins-55.64% Pretax MarginN/A Return on Equity8.53% Return on Assets1.31% Debt Debt-to-Equity Ratio0.09 Current Ratio0.50 Quick Ratio0.32 Sales & Book Value Annual Sales$682.43 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.19 Book Value$1.86 per share Price / BookN/AMiscellaneous Outstanding Shares133,152,000Free FloatN/AMarket Cap$3.60 million OptionableOptionable Beta0.95 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AKRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akorn, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akorn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.